Practice-entering researchPhase IINCT04165772
Primary analysis
Dostarlimab in dMMR locally advanced rectal cancer (MSK phase II)
Rectum
High cCR with PD-1 in dMMR LARC; trial still recruiting.
Registry checked: 2026-10-29
Clinical trials explorer
Filter by cancer type, molecular target, phase, and recruitment status.
Loading filters…
Practice-entering researchPhase IINCT05723562
Interim analysis · FDA accelerated approval — 19 October 2026 (US)
AZUR-1 — dostarlimab monotherapy in dMMR/MSI-H locally advanced rectal cancer
Rectum
FDA accelerated approval 19 Oct 2026 (US). Single-arm; confirmatory follow-up to 2029/2030. Bridge to Rectum Landmark (MSK + AZUR-1).
Registry checked: 2026-10-29
Practice-entering researchPhase IIINCT06625320
Primary analysis · FDA approval — 26 August 2026 (US)
RASolute 302 — daraxonrasib vs standard care in metastatic PDAC (phase III)
Pancreas
Phase III OS/PFS benefit vs investigator-choice chemo; FDA approval 26 Aug 2026 (US). Align with Pancreas Landmark.
Registry checked: 2026-10-29
Practice-entering researchPhase IIINCT02912559
Primary analysis · FDA approval — 8 October 2026 (US)
ATOMIC — adjuvant atezolizumab + mFOLFOX6 in stage III dMMR colon cancer
Colon
Phase III DFS benefit (NEJM 2026). FDA approval — 8 Oct 2026 (US). Primary home: Colon Landmark Atlas.
Registry checked: 2026-10-29
Practice-entering researchPhase IINCT03026140
Primary analysis
NICHE-2 — neoadjuvant nivolumab + ipilimumab in locally advanced dMMR colon cancer
Colon
NICHE-2: high pCR with neoadjuvant IO; parent NCT still has open cohorts.
Registry checked: 2026-10-29
Practice-entering researchPhase IIINCT04949113
Primary analysis
NADINA — neoadjuvant ipi+nivo vs adjuvant nivo in stage III melanoma
Melanoma
Neoadjuvant ipi+nivo improved EFS in stage III melanoma (NEJM 2024).
Registry checked: 2026-10-29
Practice-entering researchPhase IIINCT03504397
Final analysis · FDA approval (US)
SPOTLIGHT — zolbetuximab + mFOLFOX6 in CLDN18.2+ gastric adenocarcinoma
Gastric / esophageal
Zolbetuximab + chemo in CLDN18.2+ gastric/GEJ; drug approved — access varies by region.
Registry checked: 2026-10-29
Practice-entering researchPhase IIINCT04704934
Primary analysis · T-DXd FDA-approved in 2L HER2+ gastric/GEJ; DG04 is confirmatory OS (NEJM)
DESTINY-Gastric04 — T-DXd vs ramucirumab+paclitaxel in HER2+ gastric/GEJ
Gastric / esophageal
2L T-DXd OS 14.7 vs 11.4 mo (HR 0.70) vs RAM+PTX; ILD risk remains class-critical.
Registry checked: 2026-10-29
Practice-entering researchPhase IIINCT02989857
Final analysis · FDA approval (US)
ClarIDHy — ivosidenib in IDH1-mutant cholangiocarcinoma
Biliary tract
Ivosidenib in IDH1-mutant cholangiocarcinoma; trial completed, drug approved in labeled settings.
Registry checked: 2026-10-29
Practice-entering researchPhase IIINCT04039607
Primary analysis · FDA approval — 11 April 2025 (US)
CheckMate 9DW — nivolumab + ipilimumab in advanced HCC
Liver (HCC)
1L nivo+ipi OS 23.7 vs 20.6 mo (HR 0.79); FDA 11 Apr 2025 (US). Align with HCC Landmark.
Registry checked: 2026-10-29
Practice-entering researchPhase II
Primary analysis
DYNAMIC — ctDNA-guided adjuvant chemotherapy (stage II colon)
Colon
ctDNA-guided adjuvant stage II colon; 2y RFS non-inferiority; ANZCTR (no NCT).
Registry checked: 2026-10-29
Practice-entering researchPhase IINCT02008656
Primary analysis
OPRA — watch-and-wait / organ preservation after TNT (rectum)
Rectum
Watch-and-wait after TNT if cCR (OPRA); informs organ-preservation options.
Registry checked: 2026-10-29
Practice-entering researchPhase IIINCT04008030
Primary analysis · FDA approval — 8 April 2025 (US; nivo+ipi, MSI-H/dMMR mCRC)
CheckMate 8HW — nivo±ipi vs chemotherapy in MSI-H/dMMR mCRC
Colon · Rectum
Phase III MSI-H mCRC; nivo+ipi FDA 8 Apr 2025 (US). Cross-read KEYNOTE-177 Landmark — no duplicate star.
Registry checked: 2026-10-29